Verona Pharma (LON:VRP)

Verona Pharma (LON:VRP)


Share Price
59.50 p
Change
0 (0.00 %)
Market Cap
£62.67 m
Proactive Investors - Run By Investors For Investors

Verona Pharma

The Company is involved in drug discovery focused on the discovery and development of new therapeutic drugs for the treatment of allergic rhinitis (hay fever) nad other chronic respiratory and inflammatory diseases.

EPIC: VRP
Market: AIM:VRP
52-week High/Low: 159.00p / 48.00p
Sector: Pharma & Biotech
Market Cap: £62.67 m
Website: www.veronapharma.com
col 3
col 4
col 5
col 6

Verona Pharma RNS Announcements

Date Epic Announcement
04/06/2019 VRP Verona Pharma Initiates Phase 2 Clinical Trial with Metered Dose Inhaler Formulation of Ensifentrine for Maintenance Treatment of COPD
30/05/2019 VRP Verona Pharma to Present at Jefferies 2019 Global Healthcare Conference
29/05/2019 VRP PDMR Dealing
20/05/2019 VRP Verona Pharma Presents Expanded Analysis of Ensifentrine Clinical Data in COPD Maintenance Treatment at American Thoracic Society 2019 International Conference
07/05/2019 VRP Result of AGM
07/05/2019 VRP Verona Pharma plc Operational Update and Financial Results for the Three Months Ended March 31, 2019
07/05/2019 VRP Verona Pharma Initiates Additional Phase 2b Clinical Trial with Nebulized Ensifentrine to Inform Dose Selection for Phase 3 Trials
02/05/2019 VRP Verona Pharma to Present Clinical Trial Data of Ensifentrine for COPD Maintenance Treatment at American Thoracic Society 2019 International Conference
01/05/2019 VRP Verona Pharma plc ("Verona" or the "Company") Appointment of Nominated Adviser and UK Broker
01/05/2019 VRP Verona Pharma to Announce Financial Results for First Quarter Ended March 31, 2019 and Provide Clinical Development Update
25/04/2019 VRP Verona Pharma to Host Investor & Analyst R&D Forum in London on May 8, 2019
09/04/2019 VRP Verona Pharma Granted Key EU Patent Related to Late-stage COPD Clinical Candidate Ensifentrine
04/04/2019 VRP Grant of Options and RSUs and PDMR Dealings
26/03/2019 VRP Verona Pharma to Present at H.C. Wainwright Global Life Sciences Conference
25/03/2019 VRP PDMR Dealing
22/03/2019 VRP 2018 Annual Report and Accounts and Notice of AGM 
21/03/2019 VRP Dr. Martin Edwards Joins Verona Pharma as Non-Executive Director
20/03/2019 VRP PDMR Dealing
11/03/2019 VRP PDMR Dealing
07/03/2019 VRP PDMR Dealing
05/03/2019 VRP PDMR Dealing
04/03/2019 VRP Verona Pharma Reports Positive Interim Data with Ensifentrine Dry Powder Inhaler Formulation in First of Two-Part Phase 2 Clinical Trial in COPD
28/02/2019 VRP Verona Pharma to Present at Cowen and Company 39th Annual Health Care Conference
26/02/2019 VRP Verona Pharma Reports Financial Results for Full Year Ended December 31, 2018 and Provides Clinical Development Update
20/02/2019 VRP Verona Pharma to Announce Financial Results for Full Year ended December 31, 2018 and Provide Clinical Development Update
04/02/2019 VRP Verona Pharma to Present at Upcoming Investor Conferences
14/01/2019 VRP Verona Pharma Reports Encouraging Top-Line Data from Three-Day Phase 2 Trial Evaluating Nebulized Ensifentrine (RPL554) on Top of Dual Bronchodilator Therapy for COPD Maintenance Treatment
09/01/2019 VRP Verona Pharma Receives WHO Approval for “ensifentrine” as Recommended INN for RPL554
17/12/2018 VRP Verona Pharma Initiates Phase 2 Clinical Trial to Evaluate Dry Powder Inhaler Formulation of RPL554 for Maintenance Treatment of COPD
17/12/2018 VRP Verona Pharma Initiates Phase 2 Clinical Trial to Evaluate Dry Powder Inhaler Formulation of RPL554 for Maintenance Treatment of COPD
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use